Tarsus Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast

IRVINE, Calif., Oct. 29, 2026 /CourierPR/ -- Tarsus Pharmaceuticals, Inc. is set to host a live webcast on Tuesday, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. The company will report its third quarter 2026 financial results and provide a corporate update. Participants can access the webcast through a provided link, with a recorded version available shortly after the event and archived for approximately 90 days.

Tarsus Pharmaceuticals, Inc. focuses on applying proven science and new technology to revolutionize treatment for patients, starting with eye care. The company has several ongoing projects aimed at addressing high unmet needs across various therapeutic categories. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Additionally, Tarsus is developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2. The company is also advancing IRX-101 for potential use as an ocular antiseptic and gildeuretinol for the potential treatment of Stargardt disease.

The webcast will serve as a platform for Tarsus to share its financial performance and progress in its pipeline of innovative treatments. Investors and stakeholders will have the opportunity to gain insights into the company's strategic direction and future prospects.